Literature DB >> 28641369

Markers of Inflammation and Incident Breast Cancer Risk in the Women's Health Study.

Deirdre K Tobias1, Akintunde O Akinkuolie2, Paulette D Chandler1, Patrick R Lawler2,3,4, JoAnn E Manson1,5,6, Julie E Buring1,5, Paul M Ridker2,5, Lu Wang1, I-Min Lee1,5, Samia Mora2.   

Abstract

Chronic inflammation may be a risk factor for the development and progression of breast cancer, yet it is unknown which inflammatory biomarkers and pathways are especially relevant. The present study included 27,071 participants (mean age = 54.5 years) in the Women's Health Study who were free of cancer and cardiovascular disease at enrollment (1992-1995), with baseline measures of 4 inflammatory biomarkers: high-sensitivity C-reactive protein, fibrinogen, N-acetyl side-chains of acute phase proteins, and soluble intercellular adhesion molecule-1. We used Cox proportional hazards regression models to evaluate associations between baseline concentrations of biomarkers and incident breast cancer, and adjusted for baseline and time-varying factors such as age and body mass index. Self-reported invasive breast cancer was confirmed against medical records for 1,497 incident cases (90% postmenopausal). We observed different patterns of risk depending on the inflammatory biomarker. There was a significant direct association between fibrinogen and breast cancer risk (for quintile 5 vs. quintile 1, adjusted hazard ratio = 1.25, 95% confidence interval: 1.03, 1.51; P for trend = 0.01). In contrast, soluble intercellular adhesion molecule-1 was inversely associated with breast cancer (for quintile 5 vs. quintile 1, adjusted hazard ratio = 0.79, 95% confidence interval: 0.66, 0.94; P for trend = 0.02). N-acetyl side-chains of acute phase proteins and high-sensitivity C-reactive protein were not associated with breast cancer. The complex association of chronic inflammation and breast cancer may be considered when formulating anti-inflammatory cancer prevention or intervention strategies.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28641369      PMCID: PMC5889040          DOI: 10.1093/aje/kwx250

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  43 in total

1.  Flexible regression models with cubic splines.

Authors:  S Durrleman; R Simon
Journal:  Stat Med       Date:  1989-05       Impact factor: 2.373

2.  Plasma C-reactive protein and risk of breast cancer in two prospective studies and a meta-analysis.

Authors:  Jun Wang; I-Min Lee; Shelley S Tworoger; Julie E Buring; Paul M Ridker; Bernard Rosner; Susan E Hankinson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-05-20       Impact factor: 4.254

3.  Role of ICAM1 in invasion of human breast cancer cells.

Authors:  Caridad Rosette; Richard B Roth; Paul Oeth; Andreas Braun; Stefan Kammerer; Jonas Ekblom; Mikhail F Denissenko
Journal:  Carcinogenesis       Date:  2005-03-17       Impact factor: 4.944

4.  GlycA: A Composite Nuclear Magnetic Resonance Biomarker of Systemic Inflammation.

Authors:  James D Otvos; Irina Shalaurova; Justyna Wolak-Dinsmore; Margery A Connelly; Rachel H Mackey; James H Stein; Russell P Tracy
Journal:  Clin Chem       Date:  2015-03-16       Impact factor: 8.327

Review 5.  The role of fibrinogen and related fragments in tumour angiogenesis and metastasis.

Authors:  Carolyn A Staton; Nicola J Brown; Claire E Lewis
Journal:  Expert Opin Biol Ther       Date:  2003-10       Impact factor: 4.388

6.  A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.

Authors:  Paul M Ridker; Nancy R Cook; I-Min Lee; David Gordon; J Michael Gaziano; Joann E Manson; Charles H Hennekens; Julie E Buring
Journal:  N Engl J Med       Date:  2005-03-07       Impact factor: 91.245

7.  Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer.

Authors:  Kristine H Allin; Stig E Bojesen; Børge G Nordestgaard
Journal:  J Clin Oncol       Date:  2009-03-16       Impact factor: 44.544

8.  Soluble adhesion molecules (E-selectin, ICAM-1 and VCAM-1) in breast carcinoma.

Authors:  D M O'Hanlon; H Fitzsimons; J Lynch; S Tormey; C Malone; H F Given
Journal:  Eur J Cancer       Date:  2002-11       Impact factor: 9.162

9.  Expression of the cell adhesion molecules ICAM-1 and VCAM-1 in the cytosol of breast cancer tissue, benign breast tissue and corresponding sera.

Authors:  P A Regidor; R Callies; M Regidor; A E Schindler
Journal:  Eur J Gynaecol Oncol       Date:  1998       Impact factor: 0.196

10.  A novel protein glycan biomarker and future cardiovascular disease events.

Authors:  Akintunde O Akinkuolie; Julie E Buring; Paul M Ridker; Samia Mora
Journal:  J Am Heart Assoc       Date:  2014-09-23       Impact factor: 5.501

View more
  20 in total

1.  Airborne mammary carcinogens and breast cancer risk in the Sister Study.

Authors:  Nicole M Niehoff; Marilie D Gammon; Alexander P Keil; Hazel B Nichols; Lawrence S Engel; Dale P Sandler; Alexandra J White
Journal:  Environ Int       Date:  2019-06-18       Impact factor: 9.621

2.  Pre-diagnostic DNA methylation patterns differ according to mammographic breast density amongst women who subsequently develop breast cancer: a case-only study in the EPIC-Florence cohort.

Authors:  Saverio Caini; Giovanni Fiorito; Domenico Palli; Benedetta Bendinelli; Silvia Polidoro; Valentina Silvestri; Laura Ottini; Daniela Ambrogetti; Ines Zanna; Calogero Saieva; Giovanna Masala
Journal:  Breast Cancer Res Treat       Date:  2021-06-08       Impact factor: 4.872

3.  Body mass index, diet, and exercise: testing possible linkages to breast cancer risk via DNA methylation.

Authors:  Arielle S Gillman; Casey K Gardiner; Claire E Koljack; Angela D Bryan
Journal:  Breast Cancer Res Treat       Date:  2017-11-10       Impact factor: 4.872

Review 4.  Metabolic dysfunction and obesity-related cancer: Beyond obesity and metabolic syndrome.

Authors:  Sheetal Hardikar; Mary C Playdon; Prasoona Karra; Maci Winn; Svenja Pauleck; Alicja Bulsiewicz-Jacobsen; Lacie Peterson; Adriana Coletta; Jennifer Doherty; Cornelia M Ulrich; Scott A Summers; Marc Gunter
Journal:  Obesity (Silver Spring)       Date:  2022-07       Impact factor: 9.298

5.  Physical activity and risk of benign proliferative epithelial disorders of the breast, in the Women's Health Initiative.

Authors:  Rita Peila; Rowan T Chlebowski; Tarah J Ballinger; Victor Kamensky; Phyllis A Richey; Nazmus Saquib; Aladdin H Shadyab; Sylvia Wassertheil-Smoller; Thomas E Rohan
Journal:  Int J Epidemiol       Date:  2021-06-17       Impact factor: 9.685

Review 6.  Dietary inflammatory index and breast cancer risk: an updated meta-analysis of observational studies.

Authors:  Zahra Hayati; Mohammad Asghari Jafarabadi; Saeed Pirouzpanah
Journal:  Eur J Clin Nutr       Date:  2021-11-02       Impact factor: 4.884

7.  Associations of fecal microbial profiles with breast cancer and nonmalignant breast disease in the Ghana Breast Health Study.

Authors:  Doratha A Byrd; Emily Vogtmann; Zeni Wu; Yongli Han; Yunhu Wan; Joe-Nat Clegg-Lamptey; Joel Yarney; Beatrice Wiafe-Addai; Seth Wiafe; Baffour Awuah; Daniel Ansong; Kofi Nyarko; Autumn G Hullings; Xing Hua; Thomas Ahearn; James J Goedert; Jianxin Shi; Rob Knight; Jonine D Figueroa; Louise A Brinton; Montserrat Garcia-Closas; Rashmi Sinha
Journal:  Int J Cancer       Date:  2021-02-26       Impact factor: 7.316

8.  The impact of PI3K inhibitors on breast cancer cell and its tumor microenvironment.

Authors:  Hanjiao Qin; Linlin Liu; Shu Sun; Dan Zhang; Jiyao Sheng; Bingjin Li; Wei Yang
Journal:  PeerJ       Date:  2018-06-19       Impact factor: 2.984

9.  Obesity, Dietary Factors, Nutrition, and Breast Cancer Risk.

Authors:  Annina Seiler; Michelle A Chen; Ryan L Brown; Christopher P Fagundes
Journal:  Curr Breast Cancer Rep       Date:  2018-01-19

10.  Association of high-sensitivity C-reactive protein and odds of breast cancer by molecular subtype: analysis of the MEND study.

Authors:  Anjali Gupta; Taofik Oyekunle; Omolola Salako; Adetola Daramola; Olusegun Alatise; Gabriel Ogun; Adewale Adeniyi; April Deveaux; Veeral Saraiya; Allison Hall; Omobolaji Ayandipo; Thomas Olajide; Olalekan Olasehinde; Olukayode Arowolo; Adewale Adisa; Oludolapo Afuwape; Aralola Olusanya; Aderemi Adegoke; Trygve O Tollefsbol; Donna Arnett; Michael J Muehlbauer; Christopher B Newgard; Tomi Akinyemiju
Journal:  Oncotarget       Date:  2021-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.